Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Increased to $116.00 by Analysts at Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target raised by Cantor Fitzgerald from $115.00 to $116.00 in a report released on Friday, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

RARE has been the subject of a number of other research reports. Canaccord Genuity Group restated a buy rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. The Goldman Sachs Group upgraded shares of Ultragenyx Pharmaceutical from a neutral rating to a buy rating and boosted their target price for the stock from $56.00 to $67.00 in a report on Thursday, June 6th. TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a buy rating in a report on Wednesday, April 24th. Wedbush boosted their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a neutral rating in a research note on Friday. Finally, Bank of America lowered their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a buy rating for the company in a research note on Friday, May 31st. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $87.92.

Ultragenyx Pharmaceutical Stock Down 2.8 %

Shares of NASDAQ:RARE opened at $49.08 on Friday. The business’s 50 day moving average is $42.00 and its 200 day moving average is $44.49. The stock has a market cap of $4.08 billion, a P/E ratio of -6.01 and a beta of 0.56. Ultragenyx Pharmaceutical has a 52-week low of $31.52 and a 52-week high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The company had revenue of $147.03 million during the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 392.36%. The firm’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.25) earnings per share. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -6.45 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the sale, the executive vice president now owns 57,981 shares in the company, valued at approximately $2,609,145. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the sale, the executive vice president now owns 57,981 shares in the company, valued at $2,609,145. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $41.10, for a total transaction of $71,390.70. Following the transaction, the director now owns 7,248 shares in the company, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,127 shares of company stock worth $536,593 in the last three months. Insiders own 5.80% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently bought and sold shares of RARE. Candriam S.C.A. grew its stake in Ultragenyx Pharmaceutical by 33.1% in the 2nd quarter. Candriam S.C.A. now owns 688,942 shares of the biopharmaceutical company’s stock valued at $28,314,000 after acquiring an additional 171,345 shares during the last quarter. Arizona State Retirement System raised its position in shares of Ultragenyx Pharmaceutical by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 434 shares during the last quarter. Rhumbline Advisers increased its position in Ultragenyx Pharmaceutical by 5.5% during the second quarter. Rhumbline Advisers now owns 96,710 shares of the biopharmaceutical company’s stock worth $3,975,000 after buying an additional 5,047 shares in the last quarter. Privium Fund Management B.V. raised its holdings in shares of Ultragenyx Pharmaceutical by 17.0% in the second quarter. Privium Fund Management B.V. now owns 251,602 shares of the biopharmaceutical company’s stock worth $10,306,000 after acquiring an additional 36,500 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $33,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.